A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...
Novo Nordisk A/S still looks like a buy: oral Wegovy growth, solid global demand, 13x forward P/E, and buybacks support upside. Click for this NVO stock update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results